'Even more' cost synergies to Valeant/Biovail merger while headcount cut by 25%
This article was originally published in Scrip
Executive Summary
The merger of Valeant Pharmaceuticals and Biovail will see more cost synergies than previously calculated, $300 million compared with earlier guidance of $175 million, according to Valeant's CEO J. Michael Pearson.